Abstract
Targeting tumor angiogenesis to treat cancer has been the focus of intense research in recent decades. The resulting increase in our knowledge of cancer biology has lead to the development of several new classes of investigational agents that inhibit the angiogenic process. While many clinical trials on antiangiogenic compounds have had disappointing results, the recent approval of the first effective drug targeting tumor vessels has revived interest in further drug development for angiogenesis inhibitors. Of the plethora of new patents for antiangiogenic compounds, only a few describe compounds that will become effective and non-toxic therapies for patients with cancer. This review examines representative patents related to cancer angiogenesis in the context of our current knowledge of the biological processes leading to tumor vascularization and explores the future of multi-targeted therapy and nanoformulation technology in the field of angiogenic therapy.
Keywords: Tumor angiogenesis, vascular endothelial growth factor, indolinones
Recent Patents on Anti-Cancer Drug Discovery
Title: Review of Selected Patents for Cancer Therapy Targeting Tumor Angiogenesis
Volume: 1 Issue: 2
Author(s): Mark N. Kirstein, Megan M. Moore and Arkadiusz Z. Dudek
Affiliation:
Keywords: Tumor angiogenesis, vascular endothelial growth factor, indolinones
Abstract: Targeting tumor angiogenesis to treat cancer has been the focus of intense research in recent decades. The resulting increase in our knowledge of cancer biology has lead to the development of several new classes of investigational agents that inhibit the angiogenic process. While many clinical trials on antiangiogenic compounds have had disappointing results, the recent approval of the first effective drug targeting tumor vessels has revived interest in further drug development for angiogenesis inhibitors. Of the plethora of new patents for antiangiogenic compounds, only a few describe compounds that will become effective and non-toxic therapies for patients with cancer. This review examines representative patents related to cancer angiogenesis in the context of our current knowledge of the biological processes leading to tumor vascularization and explores the future of multi-targeted therapy and nanoformulation technology in the field of angiogenic therapy.
Export Options
About this article
Cite this article as:
Kirstein N. Mark, Moore M. Megan and Dudek Z. Arkadiusz, Review of Selected Patents for Cancer Therapy Targeting Tumor Angiogenesis, Recent Patents on Anti-Cancer Drug Discovery 2006; 1 (2) . https://dx.doi.org/10.2174/157489206777442269
DOI https://dx.doi.org/10.2174/157489206777442269 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Chemopreventive and Chemotherapeutic Potentials of Tea Polyphenols
Current Pharmaceutical Biotechnology Automated Brain Tumor Segmentation from MRI Images using Morphometric Algorithms
Current Signal Transduction Therapy CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Therapeutic Window, a Critical Developmental Stage for Stem Cell Therapies
Current Stem Cell Research & Therapy Targeting Inhibitor of Apoptosis Proteins (IAPs) for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Iron Oxide Nanoparticle Platform for Biomedical Applications
Current Medicinal Chemistry MTHFR Gene Polymorphism and Diabetic Retinopathy
Current Diabetes Reviews Design, Synthesis and Anticancer Activity Evaluation of Diazepinomicin Derivatives
Letters in Drug Design & Discovery Targeting the Brain: Advances in Drug Delivery
Current Pharmaceutical Biotechnology Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research Promises of Apoptosis-Inducing Peptides in Cancer Therapeutics
Current Pharmaceutical Biotechnology Targeting Tumors with Small Molecule Peptides
Current Cancer Drug Targets Antisense Strategies in Therapy of Gliomas
Current Signal Transduction Therapy Recent Developments in Targeting Breast Cancer Stem Cells
Recent Patents on Regenerative Medicine Morphological and Functional Characteristic of Senescent Cancer Cells
Current Drug Targets Ferroptosis: A Novel Mechanism of Artemisinin and its Derivatives in Cancer Therapy
Current Medicinal Chemistry Blood-Brain Barrier Transport of Drugs for the Treatment of Brain Diseases
CNS & Neurological Disorders - Drug Targets Analysis of miRNAs Targeting 3’UTR of H2AFX Gene: a General <i>in Silico</i> Approach
MicroRNA Role of the RAS in Pancreatic Cancer
Current Cancer Drug Targets